Gene
MET
MET is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (5), Assay-provider ledger (130), Actionable biomarkers (34), and 8 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
3 more sections with rows · 1 section measured, none recorded
FDA companion diagnostic
An FDA-cleared or approved companion diagnostic names this biomarker.
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention MET. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 10 at the structurally incomplete recent edge.
MET has 9 trial mentions across 8 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 30 of 11,460 | 0.26% |
| 2022 | 1 of 8,285 | 0.01% | 32 of 13,598 | 0.24% |
| 2021 | 2 of 8,692 | 0.02% | 45 of 15,045 | 0.30% |
| 2020 | 1 of 7,640 | 0.01% | 43 of 14,459 | 0.30% |
| 2019 | 1 of 7,300 | 0.01% | 43 of 12,159 | 0.35% |
| 2018 | 0 of 6,927 | 0.00% | 40 of 11,854 | 0.34% |
| 2017 | 0 of 6,558 | 0.00% | 44 of 11,595 | 0.38% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (5)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| FoundationOne CDx | MET | Foundation Medicine, Inc. | Non-small cell lung cancer (NSCLC) | 2026-05-12 |
| VENTANA MET (SP44) RxDx Assay (Ventana Medical Systems, Inc. | MET | Roche Tissue Diagnostics | Non-Small Cell Lung Cancer (NSCLC) | 2025-05-14 |
| FoundationOne Liquid CDx | MET | Foundation Medicine, Inc. | Non-Small Cell Lung Cancer (NSCLC) | 2024-11-14 |
| FoundationOne Liquid CDx | MET | Foundation Medicine, Inc. | Non-Small Cell Lung Cancer (NSCLC) | 2021-07-15 |
| FoundationOne CDx | MET | Foundation Medicine, Inc. | Non-Small Cell Lung Cancer (NSCLC) | 2020-05-06 |
Assay-provider ledger (130)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Foundation Medicine | Diagnostic provider | Clinical validationAnalytical validation | 9 | August 01, 2026 +2 undated |
| Olympus Corporation of Americas | Reagent supplier | Clinical validationAnalytical validation | 1 | August 01, 2026 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 10 | August 01, 2026 |
| University of Pittsburgh Medical Center (UPMC) Molecular & Genomics Pathology (MGP) laboratory | Not a company | Clinical validationAnalytical validation | 1 | August 01, 2026 |
| University of Minnesota Genomics Center | Not a company | Clinical validationAnalytical validation | 1 | April 01, 2026 |
Showing 5 of 130 assay-provider companies.
Actionable biomarkers (34)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| MET amplification + ERBB2 amplification | TRASTUZUMAB | responsive | breast adenocarcinoma | Cancer Genome Interpreter |
| MET amplification + BRAF (V600E) | Crizotinib | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
| MET amplification + BRAF (V600E) | Vemurafenib | responsive | colorectal adenocarcinoma | Cancer Genome Interpreter |
| MET amplification | CABOZANTINIB | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
| MET amplification | Bcl2 Inhibitors | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
Showing 5 of 34 actionable-biomarker assertions.
Trial mentions (9)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04772235 | Trial eligibility (AACT) |
| NCT04895982 | Trial eligibility (AACT) |
| NCT04085315 | Trial eligibility (AACT) |
| NCT02609776 | Trial eligibility (AACT) |
| NCT07111520 | Trial eligibility (AACT) |
Showing 5 of 9 trial mentions.
Target-disease associations (966)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 1-palmitoyl-2-palmitoleoyl-GPE (16:0/16:1) measurement | measurement | GWAS credible sets |
| 8p23.1 microdeletion syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| APC-related attenuated familial adenomatous polyposis | cancer or benign tumor | Mouse knockout (IMPC) |
| Abdominal pain | phenotype | GWAS credible sets |
Showing 5 of 966 associations.
Vendor sourcing (61)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v4.1.0 dataset. Predicted Consequence/Location: Missense variant. Missense changes are a common disease-causing mec... | View ClinVar record SCV007609992.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The MET c.901A>G, p.Thr301Ala variant (rs201687037), to our knowledge, has not been reported in the medical literature; however, this variant is listed in th... | View ClinVar record SCV002049877.2 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein functio... | View ClinVar record SCV000184457.8 |
| Baylor College of Medicine | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted without stated criteria (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV000599939.1 |
| BioNTech SE | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Male or female participants who are ≥2 years of age at the time of enrollment (Visit 1). 2. Participants or participants' parent(s)/legal guardians, as... | View trial NCT04895982 |
Showing 5 of 61 sourcing records.
Trial-cited literature (503)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS). | Nature communications | 2026 | 4 |
| MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors. | Future oncology (London, England) | 2026 | 0 |
| Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. | Annals of oncology : official journal of the European Society for Medical Oncology | 2025 | 44 |
| MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer. | NPJ precision oncology | 2025 | 6 |
| Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous <i>EGFR</i>-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024 | 162 |
Showing 5 of 503 papers.
Protein variant mentions (77)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A1384G | 1 | 2012 | PMID 22703879 |
| p.A319S | 1 | 2015 | PMID 25741868 |
| p.A320V | 1 | 2015 | PMID 25741868 |
| p.A411V | 1 | 2012 | PMID 22703879 |
| p.A48T | 1 | 2015 | PMID 25741868 |
Showing 5 of 77 variants.
Human sample screening reference (5)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.D1010H | ALCHEMIST-ALCH | Not Reported; Not Reported | 2 | 1,170 | 0.17% | 0.05% to 0.62% |
| p.D1010H | CPTAC-3 | Not Applicable; Transitional Cell Papillomas and Carcinomas; Ductal and Lobular Neoplasms; Adenomas and Adenocarcinomas; Gliomas; Epithelial Neoplasms, NOS; Complex Epithelial Neoplasms; Complex Mixed and Stromal Neoplasms; Lipomatous Neoplasms; Squamous Cell Neoplasms; Myeloid Leukemias; Nevi and Melanomas; Stomach; Other and ill-defined sites in lip, oral cavity and pharynx; Unknown; Colon; Other and unspecified urinary organs; Floor of mouth; Other and unspecified parts of mouth; Gum; Bronchus and lung; Oropharynx; Other and unspecified parts of tongue; Base of tongue; Breast; Other and ill-defined sites; Larynx; Lip; Uterus, NOS; Hematopoietic and reticuloendothelial systems; Kidney; Brain; Skin; Pancreas; Tonsil | 1 | 1,815 | 0.06% | 0.01% to 0.31% |
| p.D1028H | ALCHEMIST-ALCH | Not Reported; Not Reported | 2 | 1,170 | 0.17% | 0.05% to 0.62% |
| p.D1028H | CPTAC-3 | Not Applicable; Transitional Cell Papillomas and Carcinomas; Ductal and Lobular Neoplasms; Adenomas and Adenocarcinomas; Gliomas; Epithelial Neoplasms, NOS; Complex Epithelial Neoplasms; Complex Mixed and Stromal Neoplasms; Lipomatous Neoplasms; Squamous Cell Neoplasms; Myeloid Leukemias; Nevi and Melanomas; Stomach; Other and ill-defined sites in lip, oral cavity and pharynx; Unknown; Colon; Other and unspecified urinary organs; Floor of mouth; Other and unspecified parts of mouth; Gum; Bronchus and lung; Oropharynx; Other and unspecified parts of tongue; Base of tongue; Breast; Other and ill-defined sites; Larynx; Lip; Uterus, NOS; Hematopoietic and reticuloendothelial systems; Kidney; Brain; Skin; Pancreas; Tonsil | 1 | 1,815 | 0.06% | 0.01% to 0.31% |
| p.D1028N | ALCHEMIST-ALCH | Not Reported; Not Reported | 2 | 1,170 | 0.17% | 0.05% to 0.62% |
Literature-extracted relations (113)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Erlotinib | Chemical | negative_correlate |
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. | 2023 |
| BEVACIZUMAB | Chemical | associate |
c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial. | 2022 |
| Crizotinib | Chemical | negative_correlate |
The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program. | 2021 |
| Crizotinib | Chemical | associate |
Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-<i>MET</i> mRNA methylation. | 2020 |
| Sorafenib | Chemical | positive_correlate |
Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer. | 2020 |
Showing 5 of 113 relation assertions.
Organizations publishing (430)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The University of Texas System | Academic | 27 | 2009 to 2026 |
| Government of the United States of America | Government | 20 | 2006 to 2023 |
| Harvard Medical School | Academic | 20 | 2000 to 2026 |
| Dana-Farber Cancer Institute | Other | 19 | 2009 to 2023 |
| Mass General Brigham | Hospital | 16 | 2013 to 2026 |
Showing 5 of 430 organizations.
Where MET appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- psychiatric disorder
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
763 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects.